- Home
- NCRA vs SABS Comparison
NCRA vs SABS Comparison
Compare NCRA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCRA
- SABS
- Stock Information
- Founded
- NCRA 2002
- SABS 2014
- Country
- NCRA Taiwan
- SABS United States
- Employees
- NCRA N/A
- SABS N/A
- Industry
- NCRA Farming/Seeds/Milling
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- NCRA Consumer Staples
- SABS Health Care
- Exchange
- NCRA Nasdaq
- SABS Nasdaq
- Market Cap
- NCRA 16.8M
- SABS 19.0M
- IPO Year
- NCRA N/A
- SABS N/A
- Fundamental
- Price
- NCRA $1.01
- SABS $1.25
- Analyst Decision
- NCRA
- SABS Strong Buy
- Analyst Count
- NCRA 0
- SABS 5
- Target Price
- NCRA N/A
- SABS $11.40
- AVG Volume (30 Days)
- NCRA 20.2K
- SABS 38.1K
- Earning Date
- NCRA 05-14-2025
- SABS 05-19-2025
- Dividend Yield
- NCRA N/A
- SABS N/A
- EPS Growth
- NCRA N/A
- SABS N/A
- EPS
- NCRA N/A
- SABS N/A
- Revenue
- NCRA $20,483,694.00
- SABS $1,322,410.00
- Revenue This Year
- NCRA N/A
- SABS N/A
- Revenue Next Year
- NCRA N/A
- SABS $25.00
- P/E Ratio
- NCRA N/A
- SABS N/A
- Revenue Growth
- NCRA N/A
- SABS N/A
- 52 Week Low
- NCRA $0.70
- SABS $1.11
- 52 Week High
- NCRA $2.09
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- NCRA 51.54
- SABS 31.17
- Support Level
- NCRA $0.96
- SABS $1.11
- Resistance Level
- NCRA $1.14
- SABS $1.80
- Average True Range (ATR)
- NCRA 0.09
- SABS 0.16
- MACD
- NCRA -0.00
- SABS -0.01
- Stochastic Oscillator
- NCRA 38.71
- SABS 18.42
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.